방사선의학 웹진

바로가기  >

Abstract
Glioblastoma (GBM) is the most prevalent malignant tumor of the central nervous system and carries a poor prognosis; average survival time after diagnosis is 14 months. Because of its unfavorable prognosis, novel therapies are needed. The aim of this study was to assess whether inhibition of GBM and GBM-derived cancer stem cells (CSCs) by a new tyrosine kinase inhibitor (TKI), K905-0266, is possible. To do this, we generated GBM (D54 and U87MG) cells expressing luciferase and characterized the inhibitory effects of the TKI with bioluminescent imaging (BLI) and western blot (WB). The effect of the TKI was then evaluated in CSCs. BLI showed significant inhibition of D54 and U87MG cells by TKI treatment. WB showed that the TKI decreased pERK and Bcl-2 level and increased cleaved caspase-3 level. Sphere formation was significantly reduced by the TKI in CSCs. Our results showed that a new TKI, K905-0266, effectively inhibited GBM and CSCs, making this a candidate for GBM therapy.

K905-0266처리시 교모세포종세포의 sphere 형성이 억제됨을 보여줌.

Author information

Kalimuthu S1,2, Gangadaran P1,2,3, Oh JM1,2, Rajendran RL1,2,3, Lee HW1,2, Gopal A1,2, Hong CM1,2, Jeon YH4,5, Jeong SY1,2, Lee SW1,2, Lee J1,2, Ahn BC1,2,3.
1
Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
2
Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
3
BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
4
Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 360-4, South Korea.
5
Leading-Edge Research Center for Drug Discovery and Development for Diabetes and Metabolic Disease, Kyungpook National University Hospital, Daegu 702-210, South Korea.